Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Perrigo cleared for Zegerid OTC equivalent; Abbott Nutrition feels effects of international distribution model shift; Supreme Court passes on McNeil Tylenol preemption case; Calif. class action proceeds against POM Wonderful; multivitamins yield modest cancer-prevention benefits; study links PSE buys, meth labs.

You may also be interested in...



In Brief

Sanofi picks up Colombian generics firm Genfar; judge defers to FTC adjudication in dismissing POM Wonderful suit; P&G sues BrushPoint over whitening strip patents; Colgate, Omron team on electronic toothbrushes; more news In Brief.

State Officials Urging Rx Pseudoephedrine Face Strong Lobby

Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.

In Brief

Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel